<DOC>
	<DOCNO>NCT00276809</DOCNO>
	<brief_summary>RATIONALE : Giving combination chemotherapy peripheral blood stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , G-CSF , certain chemotherapy drug , help stem cell move bone marrow blood collect store . A monoclonal antibody , alemtuzumab , give kill remain cancer cell . Chemotherapy radiation therapy ( total-body irradiation ) give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . Giving combination chemotherapy , total-body irradiation , alemtuzumab together autologous peripheral stem cell transplant may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together total-body irradiation alemtuzumab work treat patient undergo autologous stem cell transplant stage I , stage II , stage III , stage IV chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy , Total-Body Irradiation , Alemtuzumab Treating Patients Undergoing Autologous Stem Cell Transplant Stage I , Stage II , Stage III , Stage IV Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility cytoreductive fludarabine cyclophosphamide follow high-dose myeloablative therapy comprise total-body irradiation , cyclophosphamide , alemtuzumab patient undergo autologous filgrastim ( G-CSF ) -mobilized peripheral blood stem cell transplantation stage I-IV chronic lymphocytic leukemia . Secondary - Determine clinical molecular remission rate duration patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This multicenter , open label , nonrandomized study . Patients assign 1 2 cohort accord time enrollment . - Cytoreductive induction therapy : All patient receive fludarabine IV cyclophosphamide IV day 1-3 . Treatment repeat every 28 day 2-4 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) partial response ( PR ) proceed stem cell mobilization . Patients stage III IV disease point remove study . - Stem cell mobilization : All patient receive Dexa-BEAM comprise oral dexamethasone daily day 1-10 ; carmustine IV melphalan IV day 2 ; cytarabine IV twice daily etoposide IV daily day 4-7 . Patients also receive filgrastim ( G-CSF ) subcutaneously begin day 8 continue leukapheresis complete . Patients undergo peripheral blood stem cell ( PBSC ) harvest day 20 28 . Patients without adequate number collect PBSCs may receive second course Dexa-BEAM . Patients achieve CR good PR proceed high-dose myeloablative therapy PBSC transplantation ( PBSCT ) without consolidation therapy . - Consolidation therapy : Beginning 1-2 month completion Dexa-BEAM , patient cohort 2 receive alemtuzumab IV 2 hour day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 proceed high-dose myeloablative therapy PBSCT within 1 month completion consolidation therapy . Patients cohort 1 receive consolidation therapy proceed directly high-dose therapy within 3 month completion stem cell mobilization . - High-dose myeloablative therapy PBSCT : Patients undergo total-body irradiation day -7 -5 . Patients receive cyclophosphamide IV day -4 -3 alemtuzumab IV 2 hour day -10 , -9 , -8 , -6 , -4 . Patients undergo PBSCT day 0 . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chronic lymphocytic leukemia ( CLL ) , meet 1 follow stage criterion : Stage IIV disease Binet stage B C disease Binet stage A disease high risk rapid disease progression , define follow criterion : Nonnodular marrow infiltration and/or lymphocyte double time &lt; 12 month Thymidine kinase &gt; 7.0 U/L and/or ß2microglobulin &gt; 3.5 mg/L Polymerase chain reactionamplifiable clonal CDR III rearrangement immunoglobulin variable heavy chain gene No Richter 's syndrome Bprolymphocytic leukemia PATIENT CHARACTERISTICS : ECOG performance status 01 No concurrent disease result major organ dysfunction Not pregnant nursing Fertile patient must use effective contraception No concurrent malignancy No New York Heart Association class III IV cardiac failure No cardiomyopathy No history myocardial infarction No symptomatic coronary heart disease No severe cardiac arrhythmia No severe uncontrolled hypertension No chronic pulmonary disease No pulmonary function test impairment No severe uncontrolled diabetes mellitus Bilirubin transaminase ≤ 1.5 time upper limit normal Creatinine ≤ 1.4 mg/dL No cerebral dysfunction No severe psychiatric impairment No drug addiction alcoholism Negative HIV Negative Hepatitis B C No allergy protocol drug No history anaphylactic reaction monoclonal antibodies No active infection PRIOR CONCURRENT THERAPY : No 1 prior chemotherapy regimen OR chemotherapy last &gt; 6 month No prior radiotherapy No prior treatment alemtuzumab No prior longterm ( &gt; 1 month ) systemic corticosteroid No prior therapy dexamethasone , carmustine , etoposide , cytarabine , melphalan ( DexaBEAM )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>